Follow this link:
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
Category Archives: Global News Feed
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
Here is the original post:
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
23andMe Special Committee responds to CEO’s take-private proposal
Read the original here:
23andMe Special Committee responds to CEO’s take-private proposal
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
MediWound to Report Second Quarter 2024 Financial Results
Originally posted here:
MediWound to Report Second Quarter 2024 Financial Results
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
Here is the original post:
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Go here to read the rest:
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
Read more from the original source:
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
Digicann Ventures and 3Win Corp. Sign Binding LOI for Proposed RTO Transaction
See the article here:
Digicann Ventures and 3Win Corp. Sign Binding LOI for Proposed RTO Transaction
NTG Nordic Transport Group acquires SCHMALZ+SCHÖN Holding GmbH
Avicanna Announces Changes of Auditors
Visit link:
Avicanna Announces Changes of Auditors